iBio reports single-dose IBIO-610 achieves 98% Activin E inhibition at 4 weeks in obese NHP study

iBio, Inc.

Single dose of IBIO-610 reduced active Activin E by 98% at week 4 and 97% at week 8 vs baseline in obese NHPs.
When combined with semaglutide, IBIO-610 reduced lean mass loss by 73% versus semaglutide alone.
Data supports potential for infrequent dosing and fat-selective weight loss while preserving lean mass.
Full dataset to be presented at EASD Annual Meeting in Milan, September 28 – October 2, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.